Behavioral for Malignancies

Phase-Based Estimates
1
Effectiveness
1
Safety
University of Rochester, Rochester, NY
Behavioral - Behavioral
Eligibility
18+
All Sexes
Eligible conditions
Malignancies

Study Summary

This study is evaluating whether an electronic platform can help improve the care of older patients with cancer.

See full description

Treatment Effectiveness

Study Objectives

This trial is evaluating whether Behavioral will improve 1 primary outcome and 3 secondary outcomes in patients with Malignancies. Measurement will happen over the course of 1 week.

1 week
Feasibility Retention Rate
Recruitment rates
Self-Report Completion Time
System Usability Scale

Trial Safety

Trial Design

2 Treatment Groups

Control
Experimental

This trial requires 50 total participants across 2 different treatment groups

This trial involves 2 different treatments. Behavioral is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Experimental
Behavioral
The eGAP consists of validated questionnaires that are used to assess health status of older adults with cancer. Based on patient responses, tailored recommendations will be provided.
ControlNo treatment in the control group
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Behavioral
2018
Completed Phase 4
~1160

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 week
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 1 week for reporting.

Who is running the study

Principal Investigator
K. P. L.
Kah Poh Loh, Senior Instructor, Department of Medicine, Hematology/Oncology
University of Rochester

Closest Location

University of Rochester - Rochester, NY

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 8 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Age ≥65 years
I was recently diagnosed with cancer. show original
Is able to provide consent that is informed. show original
The platform is currently in English, so it is only accessible to English speakers. show original
Age ≥21 years
Someone whom the patient discusses health-related matters with or who can be helpful is selected by the patient. show original
English-speaking
should be familiar with the patient's preferences for care show original

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of malignancies?

Add answer

The signs of various cancers in the throat, salivary glands and breast are specific. However, there remain no specific signs of any type of cancer, so the general signs and symptoms are vague.

Unverified Answer

What causes malignancies?

Add answer

Malignancies are a very complex disease, with multiple possible causes. It is vital for those physicians who care for patients with cancer to keep in mind that the best way to prevent cancer in the future is to prevent it in the first place.

Unverified Answer

Can malignancies be cured?

Add answer

Cancer of the head and neck area is curable, but most others (especially the breast, ovarian, endometrial, prostate, lung, and colon) are curable only in some patients, but not others. Most tumors are incurable.

Unverified Answer

How many people get malignancies a year in the United States?

Add answer

Approximately 250,000 people in the United States will be diagnosed with a malignancy in 2015. By 2060, the number of new diagnoses of all types of cancers in the United States is projected to be 937,000.

Unverified Answer

What is malignancies?

Add answer

There are very few benign histological subtypes of neoplasm, as determined by surgical pathologists, which are more likely to recur after gross total resection and therefore are unlikely to survive as initial diagnosis. The use of histologic subtypes of malignancy may be a prognostic factor in the future and may allow treatment or follow-up based on a common set of pathological features.

Unverified Answer

What are common treatments for malignancies?

Add answer

Results from a recent paper, only 22% of oncologists and 5 percent of palliative oncologists claimed to have treated a cancer patient with a TKI or ALK inhibitor. For most cancer types, only a few patients in one survey responded that their first-line treatment included one of these agents. Our survey highlights an opportunity to increase awareness of and use of targeted agents among oncologists. Further research is needed to determine if there is a shift in treatment preferences for metastatic cancer with ALK or EGFR inhibitors and whether increased use of the agents is associated with improved outcomes.

Unverified Answer

What is the average age someone gets malignancies?

Add answer

[Source: "

"Takapsestis\n\nTakapsestis is a genus of moths belonging to the subfamily Olethreutinae of the family Tortricidae.\n\n- "Takapsestis leptonicta"\n- "Takapsestis semirufana"\n\n- List of Tortricidae genera\n\n- tortricidae.com"

"Crambus walsinghami\n\nCrambus walsinghami is a moth in the family Crambidae.

Unverified Answer

Does malignancies run in families?

Add answer

Although a modest degree of familial aggregation was reported in both cancer families compared with the general population, suggestive but not statistically significant increased associations of cancer were identified in first degree relatives of cancer patients. There exists a need for further investigation of cancers involving familial predisposition. Future studies should seek to identify genes whose polymorphisms confer risk of a specific cancer type in relatives of all cancer patients.

Unverified Answer

What is behavioral?

Add answer

This finding suggests that higher levels of self-consciousness may help individuals navigate their physical surroundings and interact with others more successfully. Although more research is required to ascertain how this cognitive construct may affect behavior in a clinical context, these results are consistent with a number of social learning processes and theory that suggest that an awareness of others may be an important predictor of physical health/illness. (https://www.sagebrushinstitute.org/research/what-is-behavioral/).

Unverified Answer

What is the latest research for malignancies?

Add answer

Current clinical trials are very important for cancer patients. We should be alert to how to assess potential side effects that may arise from new drugs and therapies, and for patients with specific conditions. Physicians and patients should cooperate to find possible solutions to overcome the problems generated through cancer clinical trials.

Unverified Answer

What are the common side effects of behavioral?

Add answer

Patients with the behavioral disorders we studied responded quite favorably to treatment. The common adverse effects reported here seem to be dose-dependent, and in that sense, similar to that reported for other psychopharmacological agents.

Unverified Answer

How does behavioral work?

Add answer

The positive behavioral intervention is recommended for people with [head and neck cancer](https://www.withpower.com/clinical-trials/head-and-neck-cancer), who are at risk of developing serious depression related to the physical effects of cancer and/or related psychological issues, such as psychological stress and distress relating to the physical side effects of treatment. Behavioral treatment should also be provided for people who have been diagnosed with a serious and enduring physical illness who also have major psychological symptoms such as depression, stress, anxiety, or worry, but who remain active and functional. Additionally, the benefits of the intervention are similar for both patient and carer.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Malignancies by sharing your contact details with the study coordinator.